Phialogics
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.
Press releases
Press
Phialogics secures pre-seed financing for Next-Gen IgV Therapeutics to modulate immune responses in inflammatory diseases
Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation.
The startup closes a 600,000 € pre-seed financing round with High-Tech Gründerfonds.
The capital will be used to further develop Phialogics’ lead candidate in preclinical models in comparison to the current standard of care and other research approaches.
This is a step forward to continue developing Phialogics’ i
Info & Contact
Address
Phialogics AG
c/o Switzerland Innovation Park Basel Area AG
Hegenheimermattweg 167A
4123 Allschwil
Switzerland
c/o Switzerland Innovation Park Basel Area AG
Hegenheimermattweg 167A
4123 Allschwil
Switzerland
In portfolio
31. Dec 2022